Votrient

Pazopanib Shows Promise in von Hippel-Lindau Disease - A Rare Cancer Syndrome

Results from the first prospective trial of systemic treatment for von Hippel-Lindau (VHL) disease show that the antiangiogenic agent pazopanib (Votrient, Novartis) could offer a "realistic option" to surgical resection in patients with this rare, inherited cancer syndrome.